Variants of MMP-9 and TIMP-1 Levels Could be a Predictor of an Early Development of Cardiovascular Diseases in Type 2 Diabetes among Iraqi Patients

Abstract

Dysregulation of matrix metalloproteinases-9 (MMP-9) and tissue inhibitors of
matrix metalloproteinases-1 (TIMP-1) may contribute to the development of
cardiovascular diseases in type 2 diabetes mellitus (T2DM) patients. The aim of this
study was to determine the effects of chronic hyperglycemia on serum
concentrations of MMP-9 and TIMP-1of T2DM patients without dyslipidemia (one
of atherosclerosis risk factors) and with duration less than 5 years in comparison
with T2DM patients with dyslipidemia and with duration more than 10 years and
controls. Also to investigate if serum levels of MMP-9 and TIMP-1 could be
potential markers for early detection of the development of cardiovascular
complications in T2DM patients without dyslipidemia. This study consisted of 24
T2DM patients without dyslipidemia, 30 T2DM patients with dyslipidemia, and 26
healthy subjects. A variety of inflammatory markers including: MMP-9, TIMP-1,
IL18 and hs-CRP were compared among the three groups. The BMI was similar
among the three groups. A significant increase of WHR, WHtR, FPG, TC, TG,
LDL-C, VLDL-C, AIP, atherogenic ratio-1, atherogenic ratio-2, hs-CRP, MMP-9,
TIMP-1 and IL-18 with a significant decrease of HDL-C, β Cell% and S% among
the three groups. MMP-9 of T2DM patients without dyslipidemia and with duration
less than 5 years showed a significant positive correlation with FPG and a
significant negative correlation with TC. MMP-9 of T2DM patients with
dyslipidemia and with duration more than 10 years showed significant negative
correlation with LDL-C. TIMP-1 of T2DM patients with dyslipidemia and with
duration more than 10 years showed a significant negative correlation with TC, TG,
VLDL-C and atherogenic ratio-1. The significant increased levels of both MMP-9
and TIMP-1 in T2DM patients without dyslipidemia and with duration less than 5
years compared to controls showed that those patients have risk factor for
cardiovascular complications. This study suggests that MMP-9 and TIMP-1 may be
potentially useful as markers in T2DM patients at risk of progression of
cardiovascular diseases.